Gradual increasing dyslipidemia in treatment-naive male patients with human immunodeficiency virus and treated with tenofovir plus lamivudine plus efavirenz for 3 years

Abstract Introduction Since the development of antiretroviral therapy (ART) with TDF plus 3TC plus EFV, this specific regimen has not been studied enough with long-term lipid and uric acid monitoring. Methods A prospective follow-up cohort study was performed. Sixty-one treatment-naive male patients...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Dafeng Liu, Xinyi Zhang, Jun Kang, Fengjiao Gao, Yinsheng He, Shenghua He
Formato:	article
Lenguaje:	EN
Publicado:	BMC 2021
Materias:	Human immunodeficiency virus (HIV) Antiretroviral therapy (ART) Lipid metabolism parameter Uric acid Dynamic change Long-term Nutritional diseases. Deficiency diseases RC620-627
Acceso en línea:	https://doaj.org/article/5825befcd9014ff3ad85263c03fe2c1f
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:5825befcd9014ff3ad85263c03fe2c1f
record_format	dspace
spelling	oai:doaj.org-article:5825befcd9014ff3ad85263c03fe2c1f2021-11-21T12:40:17ZGradual increasing dyslipidemia in treatment-naive male patients with human immunodeficiency virus and treated with tenofovir plus lamivudine plus efavirenz for 3 years10.1186/s13098-021-00756-y1758-5996https://doaj.org/article/5825befcd9014ff3ad85263c03fe2c1f2021-11-01T00:00:00Zhttps://doi.org/10.1186/s13098-021-00756-yhttps://doaj.org/toc/1758-5996Abstract Introduction Since the development of antiretroviral therapy (ART) with TDF plus 3TC plus EFV, this specific regimen has not been studied enough with long-term lipid and uric acid monitoring. Methods A prospective follow-up cohort study was performed. Sixty-one treatment-naive male patients with human immunodeficiency virus (HIV) were divided into three groups based on their baseline CD4+ cell count (26, 12, and 23 patients in the < 200, 200 to 350, and > 350 groups, respectively). The lipid and purine metabolism parameters of the patients over 144 weeks were analyzed. Result Within 144 weeks, TG, LDL-c, TC and HDL-c gradually increased, especially TC and HDL-c (P = 0.001, 0.000, respectively). Moreover, the percentages of hyper-cholesterolemia, hyper LDL cholesterolemia, hyper-triglyceridemia and low HDL cholesterolemia also gradually increased, especially low HDL cholesterolemia significantly increased (P = 0.0007). The lower the baseline CD4+ cell counts were, the higher the TG levels and the lower the TC, LDL-c and HDL-c levels were. But there was significant difference of only baseline LDL-c levels between the three groups (P = 0.0457). No significant difference of the UA level and the percentages of hyperuricemia was found between the different follow-up time point groups or between the three CD4+ cell counts groups (all P > 0.05). The risk factors for dyslipidemia included age, anthropometric parameters and follow-up weeks, and for hyperuricemia was virus load. Conclusions Gradual increasing dyslipidemia was found in male patients with human immunodeficiency virus primarily treated with tenofovir plus lamivudine plus efavirenz for 3 years. There-fore lipid metabolism parameters should be closely monitored during long-term ART with the TDF plus 3TC plus EFV regimen.Dafeng LiuXinyi ZhangJun KangFengjiao GaoYinsheng HeShenghua HeBMCarticleHuman immunodeficiency virus (HIV)Antiretroviral therapy (ART)Lipid metabolism parameterUric acidDynamic changeLong-termNutritional diseases. Deficiency diseasesRC620-627ENDiabetology & Metabolic Syndrome, Vol 13, Iss 1, Pp 1-12 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Human immunodeficiency virus (HIV) Antiretroviral therapy (ART) Lipid metabolism parameter Uric acid Dynamic change Long-term Nutritional diseases. Deficiency diseases RC620-627
spellingShingle	Human immunodeficiency virus (HIV) Antiretroviral therapy (ART) Lipid metabolism parameter Uric acid Dynamic change Long-term Nutritional diseases. Deficiency diseases RC620-627 Dafeng Liu Xinyi Zhang Jun Kang Fengjiao Gao Yinsheng He Shenghua He Gradual increasing dyslipidemia in treatment-naive male patients with human immunodeficiency virus and treated with tenofovir plus lamivudine plus efavirenz for 3 years
description	Abstract Introduction Since the development of antiretroviral therapy (ART) with TDF plus 3TC plus EFV, this specific regimen has not been studied enough with long-term lipid and uric acid monitoring. Methods A prospective follow-up cohort study was performed. Sixty-one treatment-naive male patients with human immunodeficiency virus (HIV) were divided into three groups based on their baseline CD4+ cell count (26, 12, and 23 patients in the < 200, 200 to 350, and > 350 groups, respectively). The lipid and purine metabolism parameters of the patients over 144 weeks were analyzed. Result Within 144 weeks, TG, LDL-c, TC and HDL-c gradually increased, especially TC and HDL-c (P = 0.001, 0.000, respectively). Moreover, the percentages of hyper-cholesterolemia, hyper LDL cholesterolemia, hyper-triglyceridemia and low HDL cholesterolemia also gradually increased, especially low HDL cholesterolemia significantly increased (P = 0.0007). The lower the baseline CD4+ cell counts were, the higher the TG levels and the lower the TC, LDL-c and HDL-c levels were. But there was significant difference of only baseline LDL-c levels between the three groups (P = 0.0457). No significant difference of the UA level and the percentages of hyperuricemia was found between the different follow-up time point groups or between the three CD4+ cell counts groups (all P > 0.05). The risk factors for dyslipidemia included age, anthropometric parameters and follow-up weeks, and for hyperuricemia was virus load. Conclusions Gradual increasing dyslipidemia was found in male patients with human immunodeficiency virus primarily treated with tenofovir plus lamivudine plus efavirenz for 3 years. There-fore lipid metabolism parameters should be closely monitored during long-term ART with the TDF plus 3TC plus EFV regimen.
format	article
author	Dafeng Liu Xinyi Zhang Jun Kang Fengjiao Gao Yinsheng He Shenghua He
author_facet	Dafeng Liu Xinyi Zhang Jun Kang Fengjiao Gao Yinsheng He Shenghua He
author_sort	Dafeng Liu
title	Gradual increasing dyslipidemia in treatment-naive male patients with human immunodeficiency virus and treated with tenofovir plus lamivudine plus efavirenz for 3 years
title_short	Gradual increasing dyslipidemia in treatment-naive male patients with human immunodeficiency virus and treated with tenofovir plus lamivudine plus efavirenz for 3 years
title_full	Gradual increasing dyslipidemia in treatment-naive male patients with human immunodeficiency virus and treated with tenofovir plus lamivudine plus efavirenz for 3 years
title_fullStr	Gradual increasing dyslipidemia in treatment-naive male patients with human immunodeficiency virus and treated with tenofovir plus lamivudine plus efavirenz for 3 years
title_full_unstemmed	Gradual increasing dyslipidemia in treatment-naive male patients with human immunodeficiency virus and treated with tenofovir plus lamivudine plus efavirenz for 3 years
title_sort	gradual increasing dyslipidemia in treatment-naive male patients with human immunodeficiency virus and treated with tenofovir plus lamivudine plus efavirenz for 3 years
publisher	BMC
publishDate	2021
url	https://doaj.org/article/5825befcd9014ff3ad85263c03fe2c1f
work_keys_str_mv	AT dafengliu gradualincreasingdyslipidemiaintreatmentnaivemalepatientswithhumanimmunodeficiencyvirusandtreatedwithtenofovirpluslamivudineplusefavirenzfor3years AT xinyizhang gradualincreasingdyslipidemiaintreatmentnaivemalepatientswithhumanimmunodeficiencyvirusandtreatedwithtenofovirpluslamivudineplusefavirenzfor3years AT junkang gradualincreasingdyslipidemiaintreatmentnaivemalepatientswithhumanimmunodeficiencyvirusandtreatedwithtenofovirpluslamivudineplusefavirenzfor3years AT fengjiaogao gradualincreasingdyslipidemiaintreatmentnaivemalepatientswithhumanimmunodeficiencyvirusandtreatedwithtenofovirpluslamivudineplusefavirenzfor3years AT yinshenghe gradualincreasingdyslipidemiaintreatmentnaivemalepatientswithhumanimmunodeficiencyvirusandtreatedwithtenofovirpluslamivudineplusefavirenzfor3years AT shenghuahe gradualincreasingdyslipidemiaintreatmentnaivemalepatientswithhumanimmunodeficiencyvirusandtreatedwithtenofovirpluslamivudineplusefavirenzfor3years
_version_	1718418884089872384

Gradual increasing dyslipidemia in treatment-naive male patients with human immunodeficiency virus and treated with tenofovir plus lamivudine plus efavirenz for 3 years

Ejemplares similares